Works matching IS 01676997 AND DT 2017 AND VI 35 AND IP 2


Results: 15
    1
    2
    3
    4
    5

    Zebrafish phenotypic screen identifies novel Notch antagonists.

    Published in:
    Investigational New Drugs, 2017, v. 35, n. 2, p. 166, doi. 10.1007/s10637-016-0423-y
    By:
    • Velaithan, Vithya;
    • Okuda, Kazuhide;
    • Ng, Mei;
    • Samat, Norazwana;
    • Leong, Sze;
    • Faudzi, Siti;
    • Abas, Faridah;
    • Shaari, Khozirah;
    • Cheong, Sok;
    • Tan, Pei;
    • Patel, Vyomesh
    Publication type:
    Article
    6
    7
    8
    9
    10
    11

    A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).

    Published in:
    Investigational New Drugs, 2017, v. 35, n. 2, p. 227, doi. 10.1007/s10637-017-0436-1
    By:
    • Miura, Satoru;
    • Maemondo, Makoto;
    • Iwashima, Akira;
    • Harada, Toshiyuki;
    • Sugawara, Shunichi;
    • Kobayashi, Kunihiko;
    • Inoue, Akira;
    • Nakagawa, Taku;
    • Takiguchi, Yuichi;
    • Watanabe, Hiroshi;
    • Ishida, Takashi;
    • Terada, Masaki;
    • Kagamu, Hiroshi;
    • Gemma, Akihiko;
    • Yoshizawa, Hirohisa
    Publication type:
    Article
    12
    13

    Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.

    Published in:
    Investigational New Drugs, 2017, v. 35, n. 2, p. 235, doi. 10.1007/s10637-017-0439-y
    By:
    • Almhanna, Khaldoun;
    • Miron, Maria;
    • Wright, David;
    • Gracian, Antonio;
    • Hubner, Richard;
    • Van Laethem, Jean-Luc;
    • López, Carolina;
    • Alsina, Maria;
    • Muñoz, Frederico;
    • Bendell, Johanna;
    • Firdaus, Irfan;
    • Messersmith, Wells;
    • Ye, Zhan;
    • Fasanmade, Adedigbo;
    • Danaee, Hadi;
    • Kalebic, Thea
    Publication type:
    Article
    14
    15

    Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.

    Published in:
    Investigational New Drugs, 2017, v. 35, n. 2, p. 217, doi. 10.1007/s10637-017-0435-2
    By:
    • Tambo, Yuichi;
    • Hosomi, Yukio;
    • Sakai, Hiroshi;
    • Nogami, Naoyuki;
    • Atagi, Shinji;
    • Sasaki, Yasutsuna;
    • Kato, Terufumi;
    • Takahashi, Toshiaki;
    • Seto, Takashi;
    • Maemondo, Makoto;
    • Nokihara, Hiroshi;
    • Koyama, Ryo;
    • Nakagawa, Kazuhiko;
    • Kawaguchi, Tomoya;
    • Okamura, Yuta;
    • Nakamura, Osamu;
    • Nishio, Makoto;
    • Tamura, Tomohide
    Publication type:
    Article